DBeQ

• CAT Number: I002305
• CAS Number: 177355-84-9
• Molecular Formula: C₂₂H₂₀N₄
• Molecular Weight: 340.42
• Purity: ≥95%
• Target: p97
• Solubility: DMSO: ≥ 47 mg/mL
• Storage: Store at +4C
• IC50: 1.5 uM
• InChI: InChI=1S/C22H20N4/c1-3-9-17(10-4-1)15-23-21-19-13-7-8-14-20(19)25-22(26-21)24-16-18-11-5-2-6-12-18/h1-14H,15-16H2,(H2,23,24,25,26)
• InChIKey: QAIMUUJJAJBPCL-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)NCC4=CC=CC=C4

DBeQ (CAT: I002305) is a small-molecule inhibitor that specifically targets the protein p97 ATPase, also known as valosin-containing protein (VCP). This compound acts by binding to the N-terminal domain of p97/VCP and inhibiting its ATPase activity. By blocking p97/VCP, DBeQ disrupts various cellular processes, including protein homeostasis, DNA repair, and cell cycle regulation. DBeQ has been studied for its potential therapeutic applications in cancer, neurodegenerative diseases, and viral infections. In cancer, DBeQ has shown promising antitumor activity, inducing cytotoxicity in cancer cells and sensitizing them to chemotherapy. Additionally, DBeQ has exhibited neuroprotective effects in models of neurodegenerative disorders and antiviral activity against certain viral pathogens.

Reference

1:The AAA ATPase Vps4 Plays Important Roles in Candida albicans Hyphal Formation and is Inhibited by DBeQ. Zhang Y, Li W, Chu M, Chen H, Yu H, Fang C, Sun N, Wang Q, Luo T, Luo K, She X, Zhang M, Yang D.Mycopathologia. 2016 Jun;181(5-6):329-39. doi: 10.1007/s11046-015-9979-x. Epub 2015 Dec 23. PMID: 26700222 2:Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ.Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4834-9. doi: 10.1073/pnas.1015312108. Epub 2011 Mar 7. PMID: 21383145 Free PMC Article